Bedrijfsoverzicht
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of pharmaceutical products designed for the treatment of human diseases. Within the healthcare sector, specifically the biotechnology industry, the company focuses on creating orally delivered small molecule drugs, such as sotagliflozin, which targets conditions like hypertrophic cardiomyopathy. The organization operates with a workforce of 81 employees and holds a market capitalization of $728.73M, generating total annual revenue of $49.80M. These financial metrics position Lexicon as a mid-sized entity within the biotechnology landscape, where a market cap of $728.73M combined with revenue of $49.80M suggests a capitalization level that reflects ongoing development costs rather than mature commercial profitability. The revenue figure of $49.80M indicates a specific market footprint, while the employee count of 81 highlights a lean operational structure typical for firms in the early-to-mid stages of product commercialization.
Financiële gezondheid
The company reported a revenue of $49.80M for the trailing twelve months, accompanied by a net income of $-50,341,000 and an EBITDA of $-48,290,000. The significant disparity between the positive revenue of $49.80M and the substantial negative net income of $-50,341,000 reveals a cost structure where operating expenses, research, and development expenditures far exceed the gross profit generated from sales. This results in a free cash flow of $-47,815,248, which indicates that the company is burning cash at a rapid pace, thereby limiting its immediate financial flexibility and necessitating reliance on existing reserves or external financing to sustain operations. Profitability is severely constrained, as evidenced by a gross margin of 86.8%, an operating margin of -269.1%, and a profit margin of -101.1%, where the negative operating and profit margins confirm that the company is currently operating at a loss on a scale that outpaces its revenue generation. The balance sheet shows a cash position of $96.23M against total debt of $62.24M, with a debt-to-equity ratio of 57.87, suggesting a leveraged financial structure where debt obligations are significant relative to equity but partially offset by strong liquidity. Liquidity is robust in the short term, supported by a current ratio of 4.88, which implies the company possesses ample current assets to cover its current liabilities. However, return metrics indicate management challenges, with a return on equity of -39.7% and a return on assets of -12.6%, revealing that management has yet to generate positive returns on the capital employed in the business.
Waarderingsbeoordeling
Valuation multiples for Lexicon Pharmaceuticals reflect its pre-profitability status, with a trailing P/E ratio of N/A and a forward P/E of -8.27. The absence of a trailing P/E ratio and the negative forward P/E imply that earnings are currently negative, rendering traditional valuation multiples based on earnings per share inapplicable and suggesting that investors are pricing the stock based on future potential rather than historical earnings. Asset valuation is indicated by a price-to-book ratio of 5.81, which suggests the market values the company at a significant premium over its book value, likely reflecting intangible assets such as intellectual property and pipeline potential. Alternative valuation metrics include a price-to-sales ratio of 14.63 and an EV/EBITDA of -14.39, which further emphasize that the market is valuing the firm based on its revenue generation capabilities rather than cash flow or earnings. The stock's price range over the last year spans from a 52-week low of $0.48 to a 52-week high of $1.84, with the current trading price situated somewhere within this volatile band relative to the established high and low. Risk assessment is provided by a beta of 0.95, indicating that the stock's price volatility moves in line with the broader market, lacking significant defensive characteristics or extreme sensitivity to market swings.
Growth & Income
The company's financial trajectory shows a revenue growth of -79.3% year-over-year, while earnings growth is listed as N/A due to the company's unprofitable status. The negative revenue growth rate of -79.3% indicates a contraction in sales, which, combined with the lack of positive earnings growth, implies that the business is currently unable to scale its revenue effectively while managing costs. Lexicon Pharmaceuticals does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all available capital to fund its research and development activities rather than distributing income to shareholders. Since the company is not a dividend payer, the strategy involves reinvesting earnings—or in this case, cash reserves—into growth initiatives to potentially achieve profitability in the future. Consequently, the overall growth and income profile is characterized by significant revenue contraction and a lack of dividend income, positioning the investment entirely on the expectation of future product successes and cost reductions rather than current cash returns.